News >

Lyman Shares Blueprint for Boosting Biosimilar Uptake in Oncology

Caroline Seymour
Published: Monday, Sep 16, 2019

Gary H. Lyman, MD, MPH

Gary H. Lyman, MD, MPH
The path toward regulatory approval for a biosimilar differs from that of a biologic, but educating the medical community on that path and making data accessible to the community are important measures to take to facilitate their adoption in practice, explained Gary H. Lyman, MD, MPH.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Addressing Uncertainties in Oncology BiosimilarsApr 30, 20201.5
Community Practice Connections™: Show Me the Data™: Leveraging the Evidence to Optimize Applications of Biosimilars in CancerAug 30, 20201.5
Publication Bottom Border
Border Publication